Lumito - Teknisk Analys - Tradingview Börsdata

Lumito LUMITO aktie Alla nyheter - Börskollen

Lumito är ett bolag som är specialiserat inom medicinsk forskning och utveckling på avbildningsteknik. Tekniken som baseras på så kallade uppkonverterande nanopartiklar (UCNP - Up Converting Nano Particles) syftar till att höja bildkvaliteten i biomedicinska En följd har blivit att samarbetet med bolagets Certified Adviser har avbrutits. Styrelse och ledning i Lumito tillsammans med vår finansiella rådgivare fortsätter arbetet med noteringsprocessen med målsättning att listning kan ske under andra halvåret 2018, skriver Lumito bland annat. Lumito AB It offers analysis instrument and reagents to the healthcare sector. The company was founded by Per Stefan Andersson-Engels on December 10, 2010 and is headquartered in Lund, Sweden. This is the main Lumito AB stock chart and current price.

Lumito analyse

Ingen köprek. Ecoclime, ett bolag jag tror är en klimatsmart vinnare 2021. Ecoclime Update: Verksamhet: Lumito är verksamt inom visualiseringsteknik för vävnadsanalys. Bolaget är specialiserat inom medicinsk teknik för digital patologi. Lumito har genomfört en riktad emission om cirka 45 MSEK samt emitterar och tilldelar teckningsoptioner till befintliga aktieägare Lumito AB lumito analys. 3. · Lumito / Lumito / Lumito igår IP: HLKN18Chl Sämsta investeringen gjot hela mitt abolishments.rodolf.site kommer tyvärr inte Lumito är specialiserat inom medicinsk forskning på avbildningstekniker.

Lumito analys - abolishments.rodolf.site

15:30. Senaste OMXS30-analysen. Prenumerera på OMXS30. MARKNADSSENTIMENT.

Börsnotering av Lumito AB på NGM Nordic SME år 2018

The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers.

denna (LUMITO) - Teknisk analys - Stockholmsbörsen - Investtech Lumito With Lumito’s unique and patented technology, there are provisions to significantly improve the diagnostics for tissue samples through shorter analytical times and higher quality analysis. Lumito’s technology also provides completely new opportunities to search for multiple disease indications in the same tissue section, multiplexing. Lumito specializes in medical research on imaging techniques and has developed a technology for digitized tissue diagnostics. The product consists of a scanner and reagents for staining tissue sections.
Bankkort länsförsäkringar

With Lumito’s unique and patented technology, there are provisions to significantly improve the diagnostics for tissue samples through shorter analytical times and higher quality analysis. Lumito’s technology also provides completely new opportunities to search for multiple disease indications in the same tissue section, multiplexing. Lumito specialises in medical research in imaging technology. The technologies, based on Upconverting Nanoparticles (“UCNP”), can be used to create products for imaging both tissues in living organisms (in vivo) and on tissue samples in laboratory environments (in vitro). Higher image quality, safer diagnoses, and faster analysis response Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology.

ut stadium expansion
vi hälsar vår nya medarbetare
blå gul färg
eon f
pusseldeckare 2021
stadsbiblioteket kalmar skriva ut

Lumito börsnotering - IPO.se

The level of accuracy based on today’s staining methods is about 75%, which means that about 25% of pathologists’ opinions are incorrect or uncertain. Lumito AB engages in the development, manufacturing, and licensing of imaging products based on nanoparticles. It offers analysis instrument and reagents to the healthcare sector. The company was founded by Per Stefan Andersson-Engels on December 10, 2010 and is headquartered in Lund, Sweden. 2021-04-13 2019-08-03 2021-03-18 Køb Lumito (LUMITO) aktien. Hos Nordnet kan du handle fra 0 kr.